Healthy Extracts Inc Financials

HYEX

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Healthy Extracts Inc (HYEX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI HYEX FY2025 2026-05-14

Healthy Extracts’ apparent deleveraging in FY2025 came from a goodwill-heavy asset jump, while near-term liquidity stayed constrained.

Debt-to-equity fell from 4.8x to 0.2x in the latest year. But that cleaner leverage picture did not bring much spending flexibility: cash was only $146.9K and the current ratio stayed below 1.0x, because equity was lifted mainly by goodwill rather than liquid operating assets.

Inventory fell from $1.6M to $843K over the last two years, and that coincided with operating cash flow turning positive even though net income remained negative. That points to working-capital release as the main cash source, meaning recent cash improvement came from carrying less stock rather than from fully profitable operations.

The latest year still shows gross profit below SG&A, so higher sales have not yet covered the commercial and administrative cost base. With gross margin lower than its earlier peak, the business is selling more but keeping a thinner gross-profit cushion, which limits how much added revenue reaches the bottom line.

Financial Health Signals

Financial health score pending refresh

We are recalculating Healthy Extracts Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Piotroski F-Score Partial

3/8

Healthy Extracts Inc passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Mixed

-0.19x

For every $1 of reported earnings, Healthy Extracts Inc generates $-0.19 in operating cash flow ($166K OCF vs -$881K net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$4.5M

YoY+44.9%

5Y CAGR+28.3%

10Y CAGR+44.3%

Healthy Extracts Inc generated $4.5M in revenue in fiscal year 2025. This represents an increase of 44.9% from the prior year.

EBITDA

N/A

Net Income

-$881K

YoY-4.8%

Healthy Extracts Inc reported -$881K in net income in fiscal year 2025. This represents a decrease of 4.8% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$147K

YoY+31.2%

5Y CAGR+19.9%

10Y CAGR+57.8%

Healthy Extracts Inc held $147K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

17M

Healthy Extracts Inc had 17M shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

53.7%

YoY-7.7pp

5Y CAGR-10.5pp

10Y CAGR-6.0pp

Healthy Extracts Inc's gross margin was 53.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 7.7 percentage points from the prior year.

Operating Margin

N/A

Net Margin

-19.5%

YoY+7.5pp

5Y CAGR+178.7pp

10Y CAGR+613.0pp

Healthy Extracts Inc's net profit margin was -19.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 7.5 percentage points from the prior year.

Return on Equity

-3.7%

YoY+550.7pp

5Y CAGR+86.6pp

10Y CAGR+558.7pp

Healthy Extracts Inc's ROE was -3.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 550.7 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

HYEX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$4.5M+44.9%	$3.1M+25.2%	$2.5M+10.4%	$2.3M+34.3%	$1.7M+29.0%	$1.3M
Cost of Revenue	$2.1M+73.8%	$1.2M+39.1%	$864K-1.8%	$880K+58.0%	$557K+19.8%	$465K
Gross Profit	$2.4M+26.7%	$1.9M+17.9%	$1.6M+18.2%	$1.4M+97.3%	$695K-16.7%	$834K
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$3.4M+60.7%	$2.1M-45.8%	$3.9M+69.3%	$2.3M-11.7%	$2.6M+75.2%	$1.5M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	-$210K-12.9%	-$186K-5.3%	-$177K-173.5%	-$65K-23.3%	-$52K+28.0%	-$73K
Income Tax	$0	$0	$0	$0	N/A	N/A
Net Income	-$881K-4.8%	-$841K+66.0%	-$2.5M-151.5%	-$983K+50.5%	-$2.0M+22.9%	-$2.6M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$1.6M-4.9%	$1.7M+84.5%	$918K-5.2%	$969K+4.0%	$931K+20.8%	$771K+3.5%	$745K-18.0%	$908K
Cost of Revenue	$622K-15.6%	$737K+56.5%	$471K+25.3%	$376K-25.8%	$506K+41.9%	$357K+150.4%	$142K-66.3%	$422K
Gross Profit	$989K+3.3%	$957K+114.1%	$447K-24.6%	$593K+39.5%	$425K+2.6%	$414K-31.2%	$602K+23.9%	$486K
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$1.3M+7.4%	$1.2M+35.2%	$907K+29.9%	$698K+30.8%	$534K-12.3%	$609K+17.8%	$517K+3.8%	$498K
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$85K+153.3%	-$159K-183.8%	-$56K-92.0%	-$29K-184.7%	$35K+162.9%	-$55K-37.6%	-$40K+18.0%	-$49K
Income Tax	$0	N/A	N/A	N/A	$0	N/A	N/A	N/A
Net Income	-$201K-30.3%	-$154K+61.1%	-$395K-689.1%	$67K+116.8%	-$399K+10.8%	-$447K-226.2%	$354K+212.3%	$114K
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

HYEX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$27.8M+1070.1%	$2.4M-9.8%	$2.6M-5.3%	$2.8M-8.2%	$3.0M-2.8%	$3.1M
Current Assets	$1.3M-20.0%	$1.7M-12.6%	$1.9M-7.0%	$2.0M-11.7%	$2.3M-7.1%	$2.5M
Cash & Equivalents	$147K+31.2%	$112K+476.2%	$19K-70.4%	$66K-70.4%	$222K+275.2%	$59K
Inventory	$843K-38.0%	$1.4M-16.3%	$1.6M-10.6%	$1.8M-7.1%	$2.0M-19.0%	$2.4M
Accounts Receivable	$188K+1606.4%	$11K-63.9%	$30K-71.2%	$106K-20.7%	$133K+904.5%	$13K
Goodwill	$21.1M+10830.3%	$193K0.0%	$193K0.0%	$193K0.0%	$193K0.0%	$193K
Total Liabilities	$3.8M+92.9%	$2.0M+17.1%	$1.7M+84.7%	$910K+62.8%	$559K+113.6%	$262K
Current Liabilities	$1.7M+26.0%	$1.3M-20.3%	$1.7M+86.1%	$903K+61.5%	$559K+113.6%	$262K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$24.0M+15745.8%	$152K-84.1%	$955K-49.0%	$1.9M-24.3%	$2.5M-13.4%	$2.9M
Retained Earnings	-$20.1M-4.6%	-$19.2M-4.6%	-$18.4M-15.5%	-$15.9M-6.6%	-$14.9M-15.3%	-$13.0M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$27.3M-1.8%	$27.8M+6.2%	$26.2M+949.5%	$2.5M+3.5%	$2.4M+1.4%	$2.4M-3.6%	$2.5M-0.7%	$2.5M
Current Assets	$1.1M-18.0%	$1.3M-23.2%	$1.7M+10.8%	$1.6M+5.4%	$1.5M-10.8%	$1.7M-4.2%	$1.7M-0.9%	$1.7M
Cash & Equivalents	$164K+11.9%	$147K-22.4%	$189K-5.5%	$200K+68.8%	$119K+6.1%	$112K+11.6%	$100K-32.3%	$148K
Inventory	$521K-38.3%	$843K-12.7%	$967K-12.7%	$1.1M-3.1%	$1.1M-16.1%	$1.4M-5.3%	$1.4M+8.9%	$1.3M
Accounts Receivable	$254K+35.1%	$188K+500.5%	$31K+685.5%	$4K-94.3%	$70K+536.0%	$11K-44.3%	$20K-78.2%	$91K
Goodwill	$21.1M0.0%	$21.1M+10830.3%	$193K0.0%	$193K0.0%	$193K0.0%	$193K0.0%	$193K0.0%	$193K
Total Liabilities	$3.3M-12.1%	$3.8M+78.2%	$2.1M+5.6%	$2.0M-14.2%	$2.4M+19.5%	$2.0M+18.2%	$1.7M-20.1%	$2.1M
Current Liabilities	$1.6M-6.1%	$1.7M+43.8%	$1.2M+36.2%	$862K-63.3%	$2.4M+75.5%	$1.3M-19.5%	$1.7M-20.1%	$2.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$24.0M-0.2%	$24.0M-0.1%	$24.1M+4934.2%	$478K+689.9%	$61K-60.1%	$152K-81.1%	$803K+100.7%	$400K
Retained Earnings	-$20.3M-1.0%	-$20.1M-0.8%	-$20.0M-2.0%	-$19.6M+0.3%	-$19.6M-2.1%	-$19.2M-2.4%	-$18.8M+1.8%	-$19.1M

HYEX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$166K-41.3%	$282K+167.8%	-$416K-6.4%	-$391K+56.7%	-$901K+52.6%	-$1.9M
Capital Expenditures	N/A	N/A	$0-100.0%	$8K	$0	N/A
Free Cash Flow	N/A	N/A	-$416K-4.3%	-$399K+55.8%	-$901K	N/A
Investing Cash Flow	$56K	$0	$0+100.0%	-$5K+94.4%	-$96K+17.1%	-$116K
Financing Cash Flow	-$187K+1.3%	-$189K-151.3%	$370K+54.3%	$240K-79.4%	$1.2M-40.3%	$1.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	$106K-71.2%	$368K+231.5%	-$280K-1725.6%	$17K-71.3%	$60K+43.3%	$42K-19.9%	$52K-69.1%	$169K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$169K
Investing Cash Flow	$0-100.0%	$76K	$0+100.0%	-$19K	$0	$0	$0	$0
Financing Cash Flow	-$89K+81.8%	-$486K-280.9%	$269K+220.9%	$84K+257.4%	-$53K-76.0%	-$30K+69.8%	-$100K+7.4%	-$108K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

HYEX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	53.7%-7.7pp	61.4%-3.8pp	65.2%+4.3pp	60.9%+19.5pp	41.5%-22.8pp	64.2%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-19.5%+7.5pp	-27.0%+72.5pp	-99.5%-55.8pp	-43.7%+74.9pp	-118.5%+79.7pp	-198.3%
Return on Equity	-3.7%+550.7pp	-554.4%-295.3pp	-259.1%-206.5pp	-52.5%+27.9pp	-80.4%+9.9pp	-90.3%
Return on Assets	-3.2%+32.2pp	-35.4%+58.5pp	-93.8%-58.5pp	-35.4%+30.2pp	-65.6%+17.1pp	-82.7%
Current Ratio	0.79-0.5	1.24+0.1	1.13-1.1	2.26-1.9	4.14-5.4	9.52
Debt-to-Equity	0.16-12.8	12.97+11.2	1.76+1.3	0.49+0.3	0.23+0.1	0.09
FCF Margin	N/A	N/A	-16.7%+1.0pp	-17.7%+36.1pp	-53.8%	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	61.4%+4.9pp	56.5%+7.8pp	48.7%-12.5pp	61.2%+15.6pp	45.6%-8.1pp	53.7%-27.1pp	80.9%+27.4pp	53.5%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-12.4%-3.4pp	-9.1%+34.0pp	-43.1%-50.0pp	6.9%+49.8pp	-42.8%+15.2pp	-58.0%-105.6pp	47.6%+35.1pp	12.5%
Return on Equity	-0.8%-0.2pp	-0.6%+1.0pp	-1.6%-15.7pp	14.0%+673.2pp	-659.2%-364.2pp	-295.0%-339.2pp	44.1%+15.8pp	28.4%
Return on Assets	-0.7%-0.2pp	-0.5%+1.0pp	-1.5%-4.2pp	2.7%+19.2pp	-16.5%+2.3pp	-18.8%-33.2pp	14.4%+9.8pp	4.6%
Current Ratio	0.69-0.1	0.79-0.7	1.47-0.3	1.81+1.2	0.63-0.6	1.24+0.2	1.04+0.2	0.84
Debt-to-Equity	0.14-0.0	0.16+0.1	0.09-4.1	4.22-34.6	38.85+25.9	12.97+10.9	2.07-3.1	5.21
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	18.6%

Note: The current ratio is below 1.0 (0.79), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

MOBERG PHARMA AB PUBL MBGPF

$45.4M

Leef Brands LEEEF

$60.8M

Eagle Pharmaceut EGRX

$26.6M

C21 Investments CXXIF

$29.0M

Rubicon Organics ROMJF

$21.0M

Frequently Asked Questions

What is Healthy Extracts Inc's annual revenue?

Healthy Extracts Inc (HYEX) reported $4.5M in total revenue for fiscal year 2025. This represents a 44.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Healthy Extracts Inc's revenue growing?

Healthy Extracts Inc (HYEX) revenue grew by 44.9% year-over-year, from $3.1M to $4.5M in fiscal year 2025.

Is Healthy Extracts Inc profitable?

No, Healthy Extracts Inc (HYEX) reported a net income of -$881K in fiscal year 2025, with a net profit margin of -19.5%.

What is Healthy Extracts Inc's gross margin?

Healthy Extracts Inc (HYEX) had a gross margin of 53.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Healthy Extracts Inc's net profit margin?

Healthy Extracts Inc (HYEX) had a net profit margin of -19.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Healthy Extracts Inc's return on equity (ROE)?

Healthy Extracts Inc (HYEX) has a return on equity of -3.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Healthy Extracts Inc's operating cash flow?

Healthy Extracts Inc (HYEX) generated $166K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Healthy Extracts Inc's total assets?

Healthy Extracts Inc (HYEX) had $27.8M in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does Healthy Extracts Inc have outstanding?

Healthy Extracts Inc (HYEX) had 17M shares outstanding as of fiscal year 2025.

What is Healthy Extracts Inc's current ratio?

Healthy Extracts Inc (HYEX) had a current ratio of 0.79 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Healthy Extracts Inc's debt-to-equity ratio?

Healthy Extracts Inc (HYEX) had a debt-to-equity ratio of 0.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Healthy Extracts Inc's return on assets (ROA)?

Healthy Extracts Inc (HYEX) had a return on assets of -3.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Healthy Extracts Inc's Piotroski F-Score?

Healthy Extracts Inc (HYEX) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Healthy Extracts Inc's earnings high quality?

Healthy Extracts Inc (HYEX) has an earnings quality ratio of -0.19x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.